Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

In January, the FDA announced the approval of three of Takeda’s new once-daily DPP-4 inhibitor pills for type 2 diabetes. DPP-4 inhibitors have been the best-selling...
As noted in new now next in diaTribe #37, Novo Nordisk announced in October 2011 that it had submitted its two new “next-generation” insulin products for approval in the...
On November 28, CeQur announced that it had received CE Mark approval for its PaQ Insulin Delivery Device , allowing the product to be sold in Europe. The Swiss-based...
On February 1, the European Commission announced that it had approved Sanofi and Zealand Pharma’s GLP-1 agonist Lyxumia (lixisenatide) for type 2 diabetes. The drug is a...
A candid interview with diaTribe advisory board member Dr. Anne Peters touches on the newest drugs and devices, curing type 1, and addressing obesity.
This month, in a surprise move, Vivus announced that its weight management medication Qsymia is now available via mail order through Walmart. This is an addition to the...
A study in the Journal of the American Medical Association ( JAMA ) found that patients with type 2 diabetes who had been taking the GLP-1 agonists Bydureon (exenatide...
Two well-known endocrinologists debated the merits of inhaled insulin in the February edition of Diabetes Care.
On September 17, Vivus announced that its obesity medication Qsymia (formerly Qnexa) is now available on the US market – this happened at least several weeks earlier...
Why did Qnexa become Qsymia? diaTribe investigates the thinking behind drug names… and why they’re vital to patient safety.
On January 22, AstraZeneca (AZ) announced the approval of Xigduo (dapagliflozin and metformin hydrochloride) for the treatment of type 2 diabetes in Europe. The drug is...
At ADA this year, type 2 drugs for type 1 diabetes show lots of promise. Plus, the latest exciting data on the Medtronic Veo and hypoglycemia.
For World Diabetes Day on November 14, Abbott released a cool new interactive infographic about A Day in the Life of an Insulin-Using Patient . Approximately 26% of the...
MannKind’s inhalable ultra-rapid-acting insulin Afrezza has its day at the FDA – find out what it can do for patients and how to speak up!
A whole new approach to treating type 2 diabetes at diagnosis, a new type of metformin, and the benefit of adding a GLP-1 agonist to insulin.
The three top trends we saw in diabetes in 2013.
The Food and Drug Administration (FDA) on March 29, 2013 announced its approval of Janssen Pharmaceuticals' Invokana (canagliflozin), a new SGLT-2 inhibitor for type 2...
On March 3, AstraZeneca announced FDA approval for the Bydureon dual-chambered pen (once-weekly exenatide) to improve glycemic control in people with type 2. The device...
We ask ACA expert Dr. Jack Lord all the hard questions on healthcare coverage and reimbursement.
We travel to Oregon to support test strip access for people with diabetes. Find out what transpired!

Pages